Search Results
Feb 23, 2026, 09:00 ET ZEISS launches Collaborative Care application to strengthen continuity of care; new solution offers on-premises and cloud-based options
www.zeiss.com/med
More news about: Carl Zeiss Meditec AG
Feb 23, 2026, 06:00 ET Tim Hortons U.S. Roll Up To Win® promotion is back today through March 22
win food & beverage prizes only and are available in participating restaurants while supplies last. Odds of winning a Game Cup prize are 1:8 for Med. and 1:6 for LG/XL Game Cup. Tim Hortons App account required to participate in the Digital Roll Game. Use the App to reveal Digital Rolls; all Digital
More news about: Tim Hortons
Feb 22, 2026, 04:51 ET Lenire muestra resultados positivos consistentes para pacientes con tinnitus en Estados Unidos
retrospectiva de historias clínicas que demuestra la eficacia de la neuromodulación bimodal para el tratamiento del tinnitus en un entorno clínico Commun Med (2025). https://doi.org/10.1038/s43856-025-00837-3 4.
More news about: Neuromod Devices
Feb 20, 2026, 14:54 ET Patient Safety Movement Foundation Global Summit to Be Livestreamed Worldwide via Coresee
Panelists: Karen Phillips, Afshan Hameed, Senan Ebrahim, Emily Methangkool.During the Summit, leading organizations, hospitals and med-tech innovators will publicly share new and ongoing commitments to patient safety. These pledges reinforce that actionable, evidence-based practices,
More news about: Patient Safety Movement Foundation
Feb 20, 2026, 08:00 ET Zenocutuzumab Treatment Beyond Progression Demonstrates Continued Benefit in Patients with NRG1+ Non-Small Cell Lung Cancer: New Results from the eNRGy Trial
https://www.bizengrihcp.com/pi 4. Schram AM, Goto K, Kim DW, et al. Efficacy of zenocutuzumab in NRG1 fusion–positive cancer. N Engl J Med. 2025;392:566-76.
More news about: Partner Therapeutics, Inc.
Feb 19, 2026, 17:00 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
https://doi.org/10.1158/1078-0432.CCR-16-09517 Yang JCH, et al. Overall Survival with Amivantamab-Lazertinib in EGFR-mutant Advanced NSCLC. N Engl J Med. 2025.8 ClinicalTrials.gov. A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants
More news about: Johnson & Johnson
Feb 19, 2026, 13:23 ET Eine Weltneuheit in der Neugeborenenpflege: Japan genehmigt die zu 100 % aus Muttermilch hergestellten Nahrungsergänzungsmittel von Prolacta Bioscience als verschreibungspflichtiges Medikament für gefährdete Säuglinge.
Ernährungsbedürfnissen. „Auf der Neugeborenen-Intensivstation kann die Ernährung unserer kleinsten Patienten ihr gesamtes Leben beeinflussen", erklärte Dr. med. Kate Tauber, MA, Professorin für Pädiatrie und Leiterin des Human Milk Program am Bernard and Millie Duker Children's Hospital. „Anreicherungsmittel
More news about: Prolacta Bioscience
Feb 19, 2026, 13:10 ET SMNP Reviews Launches Flex Upgrade to Live Study Group, Expanding Access for Nurse Practitioner Board Prep
for high-stakes test prep in the U.S., offering live and self-paced online courses, private tutoring, self-study materials, and Qbanks for pre-law, pre-med, and medical school students, as well as for residents, practicing physicians, PAs, and NPs via its acquisition of Rosh Review and Sarah Michelle NP
More news about: Blueprint Test Preparation
Feb 19, 2026, 10:00 ET SkinSpirit and AmSpa Partner to Host Exclusive Cadaver Lab Training for Advanced Clinical Education
@SkinSpiritClinicSpa.About the American Med Spa Association (AmSpa)The American Med Spa Association (AmSpa) is the national organization dedicated to supporting and advancing the medical aesthetics industry.
More news about: SkinSpirit
Feb 18, 2026, 14:30 ET Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA
Jordan SC, et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. N Engl J Med. 2017 Aug 3;377(5):442-453. doi: 10.1056/NEJMoa1612567. Erratum in: N Engl J Med. 2017 Oct 26;377(17):1700. doi: 10.1056/NEJMx170015.4. Winstedt L, et al. Complete Removal of Extracellular
More news about: Hansa Biopharma AB
Feb 18, 2026, 14:28 ET Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA
Jordan SC, et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. N Engl J Med. 2017 Aug 3;377(5):442-453. doi: 10.1056/NEJMoa1612567. Erratum in: N Engl J Med. 2017 Oct 26;377(17):1700. doi: 10.1056/NEJMx170015.4. Winstedt L, et al. Complete Removal of Extracellular
More news about: Hansa Biopharma AB
Feb 18, 2026, 12:30 ET InventHelp Inventor Develops New Jewelry Making Kit (MBQ-759)
create a new jewelry making kit that would encourage creativity and offer therapeutic value," said an inventor, from Bronx, N.Y., "so I invented the MED HEAD. My design could provide a special keepsake, environmental awareness, or it can be given as a heartfelt gift."
More news about: InventHelp
Feb 18, 2026, 11:43 ET "Took my Neck From Sagging Ugly Skin to Glowing Younger-Looking Skin" -- Beverly Hills MD Rapid-Lift Advanced Neck Serum Reviews Praise Visible Neck Tightening, Lifting & Youthful Firmness
Mexico to hold a Regenerative Medicine License. Continuing their commitment to innovation and beauty, Dr. Layke and Dr. Danielpour debuted their first med spa,
More news about: Beverly Hills MD
Feb 18, 2026, 10:13 ET VIO Med Spa Brings More Glow to the Golden State, Marking California Entry in Modesto
Officially opening its doors in December 2025, VIO Med Spa Modesto marks a milestone for the brandMeet the Trio Behind VIO Med Spa in ModestoVIO Med Spa in Modesto is owned and operated by brothers Bobby and John Ismail alongside longtime
More news about: VIO Med Spa
Feb 18, 2026, 06:45 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318-1328.5 Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis — results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338.6 Griffiths CE, Reich
More news about: Eli Lilly and Company
Feb 18, 2026, 06:33 ET SGT Capital Closes Artificial Intelligence Co-Investment Fund
Co-Investment Fund, which was 25% oversubscribed. This fund strengthens SGT Capital's strategy to invest in market-leading data analytic, cybersecurity and med-tech companies. The SGT Capital AI Co-Investment Fund builds on SGT Capital's established track record in technology-enabled sectors and reflects growing
More news about: SGT Capital
Feb 18, 2026, 06:19 ET SGT Capital Closes Artificial Intelligence Co-Investment Fund
Co-Investment Fund, which was 25% oversubscribed. This fund strengthens SGT Capital's strategy to invest in market-leading data analytic, cybersecurity and med-tech companies. The SGT Capital AI Co-Investment Fund builds on SGT Capital's established track record in technology-enabled sectors and reflects growing
More news about: SGT Capital
Feb 17, 2026, 12:54 ET Lenire zeigt durchgängig positive Ergebnisse für Tinnitus-Patienten in den USA in der zweiten Peer-Review-Real-World-Studie
Retrospektive Übersichtsarbeit zum Nachweis der Wirksamkeit der bimodalen Neuromodulation bei der Tinnitus-Behandlung in einem klinischen Umfeld Commun Med (2025). https://doi.org/10.1038/s43856-025-00837-3
More news about: Neuromod Devices
Feb 17, 2026, 06:45 ET Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters
understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result
More news about: Medtronic plc
Feb 17, 2026, 05:30 ET Lenire Shows Consistent Positive Results for U.S. Tinnitus Patients in 2nd Peer-Reviewed Real-World Study
E., and Lim, H. Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment in a clinical setting Commun Med (2025). https://doi.org/10.1038/s43856-025-00837-3
More news about: Neuromod Devices
Feb 17, 2026, 05:30 ET Lenire Shows Consistent Positive Results for U.S. Tinnitus Patients in 2nd Peer-Reviewed Real-World Study
E., and Lim, H. Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment in a clinical setting Commun Med (2025). https://doi.org/10.1038/s43856-025-00837-3
More news about: Neuromod Devices
Feb 17, 2026, 05:30 ET Lenire montre des résultats positifs constants pour les patients américains souffrant d'acouphènes dans une deuxième étude en situation réelle évaluée par des pairs.
Examen rétrospectif des dossiers démontrant l'efficacité de la neuromodulation bimodale pour le traitement des acouphènes dans un cadre clinique Commun Med (2025). https://doi.org/10.1038/s43856-025-00837-3
More news about: Neuromod Devices
Feb 17, 2026, 03:00 ET Cognizant skal levere strategiske teknologitjenester til Wallenius Wilhelmsen
samarbeidspartnere som forstår virksomheten, og som hjelper oss med å operere med større presisjon og gjennomslagskraft, sier Richard Åstrand, SVP Digital Strategy Lead i Wallenius Wilhelmsen.– Cognizants kompetanse på våre løsninger i kombinasjon med deres fokus på effektivitet og praktisk teknologiadopsjon,
More news about: Cognizant Technology Solutions
Feb 16, 2026, 03:28 ET Indian Sleep-Science Startup DUSQ (formerly InnerGize) Raises ₹24 Cr to Challenge Global Sleep-Tech Leaders
foundation, we believe it can define the global sleep solutions category."The ₹24 crore seed round also marks a significant moment for Indian med-tech. The global sleep technology market has historically been dominated by U.S. and European players. Institutional backing for a deep-science platform
More news about: DUSQ
Feb 13, 2026, 16:53 ET EUROPÄISCHE KOMMISSION GENEHMIGT UPLIZNA® VON AMGEN FÜR GENERALISIERTE MYASTHENIA GRAVIS
S, Lisnic V, Leone MA. Die Epidemiologie der Myasthenia gravis. J Med Life. 2021;14(1):7-16. Nowak R, Benatar M, Ciafaloni E, et al. Eine Phase-3-Studie mit Inebilizumab bei generalisierter Myasthenia gravis. N Engl J Med. 2025;392(23):2309-2320.Europäische Arzneimittelbehörde.
More news about: Amgen